Announcement
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Thank you for attending THSNA 2026. The virtual meeting is now closed.
Presentation Details
| Paradoxical Apixaban Anti-Xa Levels After Andexanet Alfa: A Case Report on Unreliable Laboratory Monitoring and Early Thrombotic Risk Sean Twardy1, Farzeen Syed2, Shelley Kalsi2. 1Uniformed Services University of the Health Sciences, Bethesda, MD, USA.2National Institutes of Health, Bethesda, MD, USA |
Abstract
Background:
Andexanet alfa is an approved reversal agent for apixaban and rivaroxaban, but its use is complicated by thrombotic risk and significant limitations in laboratory monitoring. Standard chromogenic anti-Xa assays are known to produce artifactually elevated apixaban concentrations after andexanet administration, yet real-world perioperative cases demonstrating this effect remain limited. Objectives:
To describe a perioperative case in which andexanet alfa produced paradoxically elevated apixaban anti-Xa levels despite successful reversal and to highlight the unreliability of laboratory monitoring and the potential for early thrombotic complications following its use. Methods:
A 76-year-old male with metastatic penile squamous cell carcinoma and prior deep venous thrombosis on apixaban (5 mg twice daily) required urgent bilateral percutaneous nephrostomy (PCN) tube placement for malignant obstructive uropathy. To minimize bleeding risk, a low-dose AA regimen was administered (400 mg IV bolus followed by a 4 mg/min infusion for 120 minutes). Apixaban levels were measured at multiple time points before, during, and after AA administration using a chromogenic anti-Xa assay. Clinical, laboratory, and imaging data were reviewed throughout the hospitalization to assess thrombotic and bleeding outcomes. Results:
The pre-procedural apixaban concentration was 123 ng/mL, within the expected therapeutic range. Immediately after the AA bolus, the measured level decreased as anticipated. However, following completion of the infusion, apixaban concentrations rose sharply, reaching a paradoxical peak of 199 ng/mL, substantially higher than the pre-reversal value. These findings demonstrate profound anti-Xa assay interference from AA and indicate that such assays cannot be used to monitor true apixaban activity after reversal (Figure 1). The PCN procedure was completed without bleeding complications. Approximately 12 hours after AA administration, the patient developed transient left-sided facial droop and weakness consistent with a transient ischemic attack (TIA), occurring in the context of active malignancy, recent anticoagulation reversal, and persistent venous thromboembolism. Given his elevated thrombotic risk and the misleading anti-Xa results, anticoagulation was restarted 48 hours post-procedure based on clinical assessment rather than laboratory measurements. Conclusions:
This case highlights the critical unreliability of standard anti-Xa assays after andexanet alfa administration, as evidenced by paradoxically elevated and clinically implausible apixaban levels. These laboratory values provide no meaningful guidance for post-reversal decision-making and should not influence timing of re-anticoagulation. Additionally, the patient experienced a thrombotic event far earlier than typically reported, underscoring the need for individualized risk–benefit assessment in high-risk patients. Further research is needed to establish reliable monitoring strategies and to clarify the true timeline of thrombotic risk following AA use.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.
Andexanet alfa is an approved reversal agent for apixaban and rivaroxaban, but its use is complicated by thrombotic risk and significant limitations in laboratory monitoring. Standard chromogenic anti-Xa assays are known to produce artifactually elevated apixaban concentrations after andexanet administration, yet real-world perioperative cases demonstrating this effect remain limited. Objectives:
To describe a perioperative case in which andexanet alfa produced paradoxically elevated apixaban anti-Xa levels despite successful reversal and to highlight the unreliability of laboratory monitoring and the potential for early thrombotic complications following its use. Methods:
A 76-year-old male with metastatic penile squamous cell carcinoma and prior deep venous thrombosis on apixaban (5 mg twice daily) required urgent bilateral percutaneous nephrostomy (PCN) tube placement for malignant obstructive uropathy. To minimize bleeding risk, a low-dose AA regimen was administered (400 mg IV bolus followed by a 4 mg/min infusion for 120 minutes). Apixaban levels were measured at multiple time points before, during, and after AA administration using a chromogenic anti-Xa assay. Clinical, laboratory, and imaging data were reviewed throughout the hospitalization to assess thrombotic and bleeding outcomes. Results:
The pre-procedural apixaban concentration was 123 ng/mL, within the expected therapeutic range. Immediately after the AA bolus, the measured level decreased as anticipated. However, following completion of the infusion, apixaban concentrations rose sharply, reaching a paradoxical peak of 199 ng/mL, substantially higher than the pre-reversal value. These findings demonstrate profound anti-Xa assay interference from AA and indicate that such assays cannot be used to monitor true apixaban activity after reversal (Figure 1). The PCN procedure was completed without bleeding complications. Approximately 12 hours after AA administration, the patient developed transient left-sided facial droop and weakness consistent with a transient ischemic attack (TIA), occurring in the context of active malignancy, recent anticoagulation reversal, and persistent venous thromboembolism. Given his elevated thrombotic risk and the misleading anti-Xa results, anticoagulation was restarted 48 hours post-procedure based on clinical assessment rather than laboratory measurements. Conclusions:
This case highlights the critical unreliability of standard anti-Xa assays after andexanet alfa administration, as evidenced by paradoxically elevated and clinically implausible apixaban levels. These laboratory values provide no meaningful guidance for post-reversal decision-making and should not influence timing of re-anticoagulation. Additionally, the patient experienced a thrombotic event far earlier than typically reported, underscoring the need for individualized risk–benefit assessment in high-risk patients. Further research is needed to establish reliable monitoring strategies and to clarify the true timeline of thrombotic risk following AA use.
No part of this publication may be reproduced, distributed, or transmitted in any form or by any means, including photocopying, recording, or other electronic or mechanical methods, without the prior written permission of the author.